developments in colorectal cancer
TRANSCRIPT
![Page 1: Developments in Colorectal Cancer](https://reader036.vdocuments.us/reader036/viewer/2022070514/587e63621a28ab2a538b67b3/html5/thumbnails/1.jpg)
Developments in Colorectal Cancer
Professor Gina BrownDepartment of RadiologyRoyal Marsden Hospital
Imperial College
![Page 2: Developments in Colorectal Cancer](https://reader036.vdocuments.us/reader036/viewer/2022070514/587e63621a28ab2a538b67b3/html5/thumbnails/2.jpg)
The Royal Marsden
Objectives of Clinical Research• Earlier diagnosis of patients with suspected
cancer• Accurate prediction of tumour extent to
maximise chances of surgical cure• Understanding high-risk disease and developing
tools to identify high and low risk• Better and earlier diagnosis of potential sites of
metastatic disease –increase cure rates • Improving surveillance of patients at high risk of
recurrence.
![Page 3: Developments in Colorectal Cancer](https://reader036.vdocuments.us/reader036/viewer/2022070514/587e63621a28ab2a538b67b3/html5/thumbnails/3.jpg)
The Royal Marsden
Modern Objectives of assessing and treating Rectal Cancer
• Reduce perioperative and longterm postoperative morbidity – preserve quality of life
• Preservation of organ function• Minimise/eliminate risk of local recurrence:
selective radiotherapy and good surgery• Reduce risk of distant spread of tumour:
surveillance and modern chemotherapy
![Page 4: Developments in Colorectal Cancer](https://reader036.vdocuments.us/reader036/viewer/2022070514/587e63621a28ab2a538b67b3/html5/thumbnails/4.jpg)
The Royal Marsden
Nodal status predicts recurrence when poor surgeryis performed
Patients undergoing non-TME / TME surgery with incomplete specimens –
nodal status strongly predicts local recurrence
18% incomplete rates- Dutch TME15% - CR07North American Trials – non TME surgery5% - MERCURY
Nodes left behind cause pelvic recurrence
![Page 5: Developments in Colorectal Cancer](https://reader036.vdocuments.us/reader036/viewer/2022070514/587e63621a28ab2a538b67b3/html5/thumbnails/5.jpg)
The Royal MarsdenImprovements in Surgery and Training of Surgeons brought about a dramatic reduction in recurrence rates. Nodes were no longer a risk factor for pelvic recurrence. Improvements in surgery took almost 20 years to be accepted.
Investment in clinical surgical research could have brought about these changes sooner
![Page 6: Developments in Colorectal Cancer](https://reader036.vdocuments.us/reader036/viewer/2022070514/587e63621a28ab2a538b67b3/html5/thumbnails/6.jpg)
The Royal Marsden
MRI assessment at diagnosis enables patients with good prognosis who would not benefit from additional radiotherapy to
be identified
Taylor et al, MERCURY
Annals of Surgery 2011
![Page 7: Developments in Colorectal Cancer](https://reader036.vdocuments.us/reader036/viewer/2022070514/587e63621a28ab2a538b67b3/html5/thumbnails/7.jpg)
The Royal Marsden
Imaging Research by the MERCURY research group led to a change in the
national guidelines • Preoperative radiotherapy is not
indicated for MRI defined margin safe early T3 tumours
• Distinction between T2 and T3 no longer influences preoperative treatment choice
![Page 8: Developments in Colorectal Cancer](https://reader036.vdocuments.us/reader036/viewer/2022070514/587e63621a28ab2a538b67b3/html5/thumbnails/8.jpg)
The Royal Marsden
Problems encountered when Mri is not used to plan the operatiob
‘WAIST’ at Puborectalis
Tumour is exposed leading to CRM involvement and likelihoodof recurrence
‘Standard’ APE
Tumour is exposed
![Page 9: Developments in Colorectal Cancer](https://reader036.vdocuments.us/reader036/viewer/2022070514/587e63621a28ab2a538b67b3/html5/thumbnails/9.jpg)
The Royal Marsden
Slice 1 Slice 2
Slice 4Slice 3
Slice 5 Slice 6
Slice 1 Slice 2
Slice 3
Slice 6
Slice 4
Slice 5
The MRI scan enables the surgeon to plan the surgery more precisely and avoid tumour at the circumferential margins of resection
Mesorectal fasciaForms the surgical plane
vessels
Lymph nodes
Distance to CRM
Depth of spread/mm
![Page 10: Developments in Colorectal Cancer](https://reader036.vdocuments.us/reader036/viewer/2022070514/587e63621a28ab2a538b67b3/html5/thumbnails/10.jpg)
Sigmoid Cancer is a problemthese are a large proportion of colorectal cancers and outcomes are not as good as rectal cancer
Dis Colon Rectum. 2010 Jan;53(1):57-64.
![Page 11: Developments in Colorectal Cancer](https://reader036.vdocuments.us/reader036/viewer/2022070514/587e63621a28ab2a538b67b3/html5/thumbnails/11.jpg)
High risk features seen in a sigmoid cancer – MRI is not routinely performed but risks can be similar as
for rectal cancer
• Tumour involving non peritonealised fascial margin
• Tumour penetration of adjacent organs
• Extramural venous invasion• Depth of extramural spread
>5mm• Operation would result in a high
risk of pelvic recurrence
![Page 12: Developments in Colorectal Cancer](https://reader036.vdocuments.us/reader036/viewer/2022070514/587e63621a28ab2a538b67b3/html5/thumbnails/12.jpg)
Eur J Surg Oncol. 2005 Oct;31(8):845-53.
Improved survival being seen in rectal cancer but
not so good for colon cancer
![Page 13: Developments in Colorectal Cancer](https://reader036.vdocuments.us/reader036/viewer/2022070514/587e63621a28ab2a538b67b3/html5/thumbnails/13.jpg)
Why we should focus our attention on sigmoid cancer
assessment by MRI Sigmoid cancer has a high recurrence rate Sigmoid cancer has a worse outcome than rectal
cancer MRI is able to identify poor prognostic tumours
preoperatively Preoperative staging enhances optimal treatment
strategy including neoadjuvant treatment Sigmoid cancer with poor prognostic features
should be discussed for neoadjuvant treatment
![Page 14: Developments in Colorectal Cancer](https://reader036.vdocuments.us/reader036/viewer/2022070514/587e63621a28ab2a538b67b3/html5/thumbnails/14.jpg)
The Royal Marsden
A Patient with a Low Rectal Cancer treated by PreoperativeChemoradiotherapy : on the post treatment scan the tumour has regressed so that no obvious tumour remainsPatients, will, in future be offered the opportunity to defer their Until such time that there is evidence that the tumour is viable and regrowing. For some patients this deferral may be permanent.
![Page 15: Developments in Colorectal Cancer](https://reader036.vdocuments.us/reader036/viewer/2022070514/587e63621a28ab2a538b67b3/html5/thumbnails/15.jpg)
The Royal Marsden
2010
2007
Deferral of surgery trialPatients undergoing preop RT/CRT
![Page 16: Developments in Colorectal Cancer](https://reader036.vdocuments.us/reader036/viewer/2022070514/587e63621a28ab2a538b67b3/html5/thumbnails/16.jpg)
The Royal Marsden
A CB
Tumour present at 6 wks No tumour at 16 wksBaseline pretreatment
![Page 17: Developments in Colorectal Cancer](https://reader036.vdocuments.us/reader036/viewer/2022070514/587e63621a28ab2a538b67b3/html5/thumbnails/17.jpg)
The Royal Marsden
Current National Phase II/III
trial – TRIGGER - offering the possbility of
deferring surgery for patients with a good
response and intensifying treatment for those with a
poor response to radiotherapy
![Page 18: Developments in Colorectal Cancer](https://reader036.vdocuments.us/reader036/viewer/2022070514/587e63621a28ab2a538b67b3/html5/thumbnails/18.jpg)
The Royal MarsdenCharacteristic features of blood vessel invasion as seen on MRI and histology
• Expansion of vessels by tumour
• tubular extension of tumour signal
MRI for detection of extramural vascular invasion in rectal cancer. AJR Am J Roentgenol 191(5): 1517-1522.
![Page 19: Developments in Colorectal Cancer](https://reader036.vdocuments.us/reader036/viewer/2022070514/587e63621a28ab2a538b67b3/html5/thumbnails/19.jpg)
The Royal Marsden
Gross tubular extension along the course of lateral rectal vein
How tumour can spread within the pelvis
![Page 20: Developments in Colorectal Cancer](https://reader036.vdocuments.us/reader036/viewer/2022070514/587e63621a28ab2a538b67b3/html5/thumbnails/20.jpg)
The Royal Marsden
0
20
40
60
80
100
0 1 2 3 4 5 6
Time since operation (Years)
% R
elap
se-f
ree
MRI-EMVI score= 0-2MRI-EMVI score= 3-4
p = 0.0015
Smith et al BJS 2008, 95(2): 229-236
Prognostic significance of magnetic resonance imaging-detected extramural vascular invasion in rectal cancer
Only 30% of patients with mrEMVI were free of tumour at 3 years compared withalmost 80% disease free if negative for EMVI
![Page 21: Developments in Colorectal Cancer](https://reader036.vdocuments.us/reader036/viewer/2022070514/587e63621a28ab2a538b67b3/html5/thumbnails/21.jpg)
The Royal Marsden
Patient with vascular invasion detected on MRI, despite the success of surgery the patients developed irresectable liver metastases after 1 year.
The MRI identification of this risk factor before surgery could
1. Have helped to intensify preoperative treatment
2. Improved the monitoring and surveillance of the patient’s liver
![Page 22: Developments in Colorectal Cancer](https://reader036.vdocuments.us/reader036/viewer/2022070514/587e63621a28ab2a538b67b3/html5/thumbnails/22.jpg)
The Royal Marsden
Odds ratio 4.6 (95% CI 1.3-
16.2)P=0.01
Odds Ratio 4.6(95% CI 2.9-
14.4)P=0.001
94 low risk 136 high risk
Whole group:33/230 (14.3%) distant
mets on PET/CT
230 patients with all imaging available
6 patients (2.5%) imaging unavailable for review236 patients enrolled
5/94 (5.3%) distant mets on PET/CT
28/136 (20.6%)distant mets on PET/CT
Same mets
PET/CT and CT
2/94(2.1%)
Same mets
PET/CT and CT10/136 (7.4%)
CT mets & more mets on PET/CT
2/94(2.1%)
CT Mets & more mets on PET/CT8/136 (5.9%)
Mets only on PET/CT
1/94(1.1%)
Mets only on PET/CT10/136 (7.4%)
Any mets on PET/CT not CT
3/94 (3.2%)
Any mets on PET/CT not CT
18/136 (13.2%)
T Vuong, A Garant, G Artho
R Lisbona
McGill University Health Centre
Patients with high risk features on MRI have a much higher rate of having spread elswhere (for example liver and lungs) but these can be successfully treated by surgery and chemotherapy if detected early. High risk patients should also benefit from more intensive surveillance
![Page 23: Developments in Colorectal Cancer](https://reader036.vdocuments.us/reader036/viewer/2022070514/587e63621a28ab2a538b67b3/html5/thumbnails/23.jpg)
The Royal Marsden
A lot of funding has been invested into the investigation of tumour DNA and RNABut so far it has not been possible to demonstrate a common link that predicts how aggressively the tumour will behave or how it will respond
![Page 24: Developments in Colorectal Cancer](https://reader036.vdocuments.us/reader036/viewer/2022070514/587e63621a28ab2a538b67b3/html5/thumbnails/24.jpg)
The Royal Marsden CANCER: 1948In 1948 most patients did not survive more than a few months with a diagnosis of advanced cancer
![Page 25: Developments in Colorectal Cancer](https://reader036.vdocuments.us/reader036/viewer/2022070514/587e63621a28ab2a538b67b3/html5/thumbnails/25.jpg)
The Royal Marsden
Surgery – beyond TME – extended APE / extenteration
In 2016 the majority of patients with advanced cancerCan expect to survive complex surgery – however this requires referral and expertise in specialist centres
![Page 26: Developments in Colorectal Cancer](https://reader036.vdocuments.us/reader036/viewer/2022070514/587e63621a28ab2a538b67b3/html5/thumbnails/26.jpg)
The Royal Marsden
Irresectable Tumour
![Page 27: Developments in Colorectal Cancer](https://reader036.vdocuments.us/reader036/viewer/2022070514/587e63621a28ab2a538b67b3/html5/thumbnails/27.jpg)
The Royal Marsden
Pelvis
![Page 28: Developments in Colorectal Cancer](https://reader036.vdocuments.us/reader036/viewer/2022070514/587e63621a28ab2a538b67b3/html5/thumbnails/28.jpg)
The Royal Marsden Before MDTs and imaging
![Page 29: Developments in Colorectal Cancer](https://reader036.vdocuments.us/reader036/viewer/2022070514/587e63621a28ab2a538b67b3/html5/thumbnails/29.jpg)
The Royal Marsden
![Page 30: Developments in Colorectal Cancer](https://reader036.vdocuments.us/reader036/viewer/2022070514/587e63621a28ab2a538b67b3/html5/thumbnails/30.jpg)
Image-guidance capable radiation treatment machines
Jaffray, D. A. (2012) Image-guided radiotherapy: from current concept to future perspectivesNat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2012.194
![Page 31: Developments in Colorectal Cancer](https://reader036.vdocuments.us/reader036/viewer/2022070514/587e63621a28ab2a538b67b3/html5/thumbnails/31.jpg)
The Royal Marsden
Dose painting tumour
![Page 32: Developments in Colorectal Cancer](https://reader036.vdocuments.us/reader036/viewer/2022070514/587e63621a28ab2a538b67b3/html5/thumbnails/32.jpg)
The Royal Marsden
Putting it altogether
• Maximising information to surgeon• Enabling oncologists to seek out better
treatments for poor response to current treatment
• Giving patients the ability to avoid surgery altogether when non surgical treatment has had a good effect